PET/MRI and prostate cancer

Morand Piert, Issam El Naqa, Mathew S. Davenport, Elena Incerti, Paola Mapelli, Maria Picchio

Research output: Contribution to journalReview articlepeer-review


Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen.

Original languageEnglish
Pages (from-to)473-485
Number of pages13
JournalClinical and Translational Imaging
Issue number6
Publication statusPublished - Dec 1 2016


  • Prostate cancer
  • [C]choline
  • [F]choline
  • [Ga]PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET/MRI and prostate cancer'. Together they form a unique fingerprint.

Cite this